Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials
2010 (English)In: CURRENT OPINION IN MOLECULAR THERAPEUTICS, ISSN 1464-8431, Vol. 12, no 6, 703-711 p.Article, review/survey (Refereed) Published
Few breakthroughs in preclinical research have translated into meaningful benefits, either in clinical terms or quality of life, for patients with advanced colorectal cancer, despite important preclinical discoveries regarding aberrant biological pathways associated with disease development and progression. The many reasons for the slow progress are diverse, ranging from the failure to codevelop biomarkers and targeted therapies, the regulatory burdens imposed on academic investigators, and the failure to collect serial tumor biopsies during clinical trials. This review discusses promising translational research that could help reduce the disparity between preclinical discovery and patient benefit, and advocate the concentration of efforts and resources on the most promising therapeutic targets in colorectal cancer, such as EGFR, VEGF and Fc gamma receptor.
Place, publisher, year, edition, pages
Thomson Scientific , 2010. Vol. 12, no 6, 703-711 p.
Biomarker, colorectal cancer, drug development, EGFR, Fc gamma receptor, immunotherapy, translational research, VEGF
Engineering and Technology
IdentifiersURN: urn:nbn:se:liu:diva-64389ISI: 000285308300009OAI: oai:DiVA.org:liu-64389DiVA: diva2:390131